Basit öğe kaydını göster

dc.contributor.authorAydiner, A
dc.contributor.authorTas, Faruk
dc.contributor.authorSaip, P
dc.contributor.authorTopuz, E
dc.contributor.authorEralp, Y
dc.date.accessioned2021-03-04T12:10:54Z
dc.date.available2021-03-04T12:10:54Z
dc.date.issued2001
dc.identifier.citationEralp Y., Aydiner A., Tas F., Saip P., Topuz E., "Stevens-Johnson syndrome in a patient receiving anticonvulsant therapy during cranial irradiation.", American journal of clinical oncology, cilt.24, sa.4, ss.347-50, 2001
dc.identifier.issn0277-3732
dc.identifier.otherav_7602f787-599a-4ebe-9aff-aba36082f986
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/81057
dc.identifier.urihttps://doi.org/10.1097/00000421-200108000-00005
dc.description.abstractA 28-year-old female patient with a recent history of breast carcinoma was referred to our clinic with generalized necrotic skin eruptions and severe mucosal erosions, which developed right after the completion of cranial radiotherapy for brain metastases. She had been receiving prophylactic diphenylhydantoin treatment 100 mg three times daily during radiation therapy. The extensive involvement of the oral mucosa with conjunctivitis and synechiae of the eyelids, facial swelling, and extension of the rash over the trunk and shoulders with bullous detachment of less than 10% of the total body surface strongly suggested Stevens-Johnson syndrome caused by phenytoin treatment in our patient. There has been conflicting evidence on the role of radiotherapy in the increased risk of severe drug reactions. Although various authors have emphasized the augmented rate of severe mucocutaneous reactions caused by anticonvulsants given during radiotherapy and suggested discontinuing the prophylactic use of such drugs in patients with no history of seizures, others have argued in favor of prophylactic anticonvulsants. Given the high risk of seizures, reaching 20% in patients with brain tumors, and the low incidence of drug reactions, the suggestion of refraining from prophylactic anticonvulsants in the setting of primary or metastatic brain tumors is controversial.
dc.language.isoeng
dc.subjectSağlık Bilimleri
dc.subjectOnkoloji
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.titleStevens-Johnson syndrome in a patient receiving anticonvulsant therapy during cranial irradiation.
dc.typeMakale
dc.relation.journalAmerican journal of clinical oncology
dc.contributor.department, ,
dc.identifier.volume24
dc.identifier.issue4
dc.identifier.startpage347
dc.identifier.endpage50
dc.contributor.firstauthorID162549


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster